{
  "success": true,
  "sourceFile": "C:\\Users\\panik\\Documents\\GitHub\\Protcol2USDMv3\\input\\trial\\NCT03347396_CARDINAL\\NCT03347396_CARDINAL_SAP.pdf",
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39
  ],
  "modelUsed": "gemini-3-flash-preview",
  "sapData": {
    "analysisPopulations": [
      {
        "id": "pop_1",
        "name": "Full Analysis Set",
        "text": "The Full Analysis Set (FAS) is defined as all subjects who received at least one dose of study drug (BIVV009). The FAS will be the primary population for the efficacy analysis.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "FAS",
        "populationDescription": "The Full Analysis Set (FAS) is defined as all subjects who received at least one dose of study drug (BIVV009). The FAS will be the primary population for the efficacy analysis.",
        "criteria": "Received >=1 dose of study drug"
      },
      {
        "id": "pop_2",
        "name": "Per-protocol Set",
        "text": "The Per-protocol (PP) Set is a subset of the FAS and will include those subjects who completed the 26-week treatment period and did not have any major protocol deviations that would impact the primary efficacy endpoint.",
        "populationType": "Efficacy",
        "instanceType": "AnalysisPopulation",
        "label": "PP",
        "populationDescription": "The Per-protocol (PP) Set is a subset of the FAS and will include those subjects who completed the 26-week treatment period and did not have any major protocol deviations that would impact the primary efficacy endpoint.",
        "criteria": "Subset of FAS AND completed 26-week treatment AND no major protocol deviations impacting primary endpoint"
      },
      {
        "id": "pop_3",
        "name": "Safety Analysis Set",
        "text": "The Safety Analysis Set is defined as all subjects who received at least one dose of study drug. This population will be used for all safety analyses.",
        "populationType": "Safety",
        "instanceType": "AnalysisPopulation",
        "label": "SAF",
        "populationDescription": "The Safety Analysis Set is defined as all subjects who received at least one dose of study drug. This population will be used for all safety analyses.",
        "criteria": "Received >=1 dose of study drug"
      },
      {
        "id": "pop_4",
        "name": "PK Analysis Set",
        "text": "The PK Analysis Set is defined as all subjects who received at least one dose of study drug and have at least one evaluable PK sample.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PK",
        "populationDescription": "The PK Analysis Set is defined as all subjects who received at least one dose of study drug and have at least one evaluable PK sample.",
        "criteria": "Received >=1 dose of study drug AND has >=1 evaluable PK sample"
      },
      {
        "id": "pop_5",
        "name": "PD Analysis Set",
        "text": "The PD Analysis Set is defined as all subjects who received at least one dose of study drug and have at least one evaluable PD sample.",
        "populationType": "PK/PD",
        "instanceType": "AnalysisPopulation",
        "label": "PD",
        "populationDescription": "The PD Analysis Set is defined as all subjects who received at least one dose of study drug and have at least one evaluable PD sample.",
        "criteria": "Received >=1 dose of study drug AND has >=1 evaluable PD sample"
      }
    ],
    "characteristics": [
      {
        "id": "char_1",
        "name": "Hemoglobin",
        "code": "HEMOGLOBIN",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Hemoglobin",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Hemoglobin (Hgb) level in g/dL"
      },
      {
        "id": "char_2",
        "name": "Bilirubin",
        "code": "BILIRUBIN",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Bilirubin",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Total bilirubin levels excluding patients with Gilbertâ€™s Syndrome"
      },
      {
        "id": "char_3",
        "name": "FACIT-Fatigue Score",
        "code": "FACIT-FATIGUE_SCORE",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "FACIT-Fatigue Score",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "Functional Assessment of Chronic Illness Therapy-Fatigue scale score"
      },
      {
        "id": "char_4",
        "name": "Lactate Dehydrogenase",
        "code": "LACTATE_DEHYDROGENAS",
        "codeSystem": "http://www.cdisc.org/baseline-characteristics",
        "codeSystemVersion": "2024-03-29",
        "decode": "Lactate Dehydrogenase",
        "dataType": "Numeric",
        "instanceType": "Characteristic",
        "description": "LDH levels as a marker of hemolysis"
      }
    ],
    "summary": {
      "populationCount": 5,
      "characteristicCount": 4
    }
  }
}